Anish Thomas
Anish Thomas
National Cancer Institute, NIH
Verified email at - Homepage
Cited by
Cited by
Antibody–drug conjugates for cancer therapy
A Thomas, BA Teicher, R Hassan
The Lancet Oncology 17 (6), e254-e262, 2016
Refining the treatment of NSCLC according to histological and molecular subtypes
A Thomas, SV Liu, DS Subramaniam, G Giaccone
Nature reviews Clinical oncology 12 (9), 511, 2015
Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression
R Hassan, AC Miller, E Sharon, A Thomas, JC Reynolds, A Ling, ...
Science translational medicine 5 (208), 208ra147-208ra147, 2013
Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology clinical practice guideline
HL Kindler, N Ismaila, SG Armato III, R Bueno, M Hesdorffer, T Jahan, ...
Journal of clinical oncology: official journal of the American Society of …, 2018
Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial
A Lopez-Chavez, A Thomas, A Rajan, M Raffeld, B Morrow, R Kelly, ...
Journal of clinical oncology 33 (9), 1000, 2015
Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial
A Thomas, A Rajan, A Berman, Y Tomita, C Brzezniak, MJ Lee, S Lee, ...
The Lancet Oncology 16 (2), 177-186, 2015
Mesothelin immunotherapy for cancer: ready for prime time?
R Hassan, A Thomas, C Alewine, DT Le, EM Jaffee, I Pastan
Journal of Clinical Oncology 34 (34), 4171, 2016
Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma
R Hassan, HL Kindler, T Jahan, L Bazhenova, M Reck, A Thomas, ...
Clinical cancer research 20 (23), 5927-5936, 2014
Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front‐line therapy of pleural mesothelioma and correlation of tumor …
R Hassan, E Sharon, A Thomas, J Zhang, A Ling, M Miettinen, ...
Cancer 120 (21), 3311-3319, 2014
Second malignancies after multiple myeloma: from 1960s to 2010s
A Thomas, S Mailankody, N Korde, SY Kristinsson, I Turesson, ...
Blood, The Journal of the American Society of Hematology 119 (12), 2731-2737, 2012
A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer
RJ Kelly, A Thomas, A Rajan, G Chun, A Lopez-Chavez, E Szabo, ...
Annals of oncology 24 (10), 2601-2606, 2013
Immunotherapies for non-small-cell lung cancer and mesothelioma
A Thomas, R Hassan
The lancet oncology 13 (7), e301-e310, 2012
New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas
BT Mossman, A Shukla, NH Heintz, CF Verschraegen, A Thomas, ...
The American journal of pathology 182 (4), 1065-1077, 2013
Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial
A Rajan, CA Carter, A Berman, L Cao, RJ Kelly, A Thomas, S Khozin, ...
The lancet oncology 15 (2), 191-200, 2014
Mutations of epigenetic regulatory genes are common in thymic carcinomas
Y Wang, A Thomas, C Lau, A Rajan, Y Zhu, JK Killian, I Petrini, T Pham, ...
Scientific reports 4 (1), 1-11, 2014
Malignant mesothelioma effusions are infiltrated by CD3+ T cells highly expressing PD-L1 and the PD-L1+ tumor cells within these effusions are susceptible to ADCC by the anti …
S Khanna, A Thomas, D Abate-Daga, J Zhang, B Morrow, SM Steinberg, ...
Journal of Thoracic Oncology 11 (11), 1993-2005, 2016
Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced unresectable mesothelioma from the JAVELIN solid tumor phase Ib trial: Safety, clinical activity, and PD-L1 expression.
R Hassan, A Thomas, MR Patel, JJ Nemunaitis, J Bennouna, ...
Journal of Clinical Oncology 34 (15_suppl), 8503-8503, 2016
Sevelamer does not decrease lipopolysaccharide or soluble CD14 levels but decreases soluble tissue factor, low-density lipoprotein (LDL) cholesterol, and oxidized LDL …
NG Sandler, X Zhang, RJ Bosch, NT Funderburg, AI Choi, JK Robinson, ...
The Journal of infectious diseases 210 (10), 1549-1554, 2014
Targeting the epigenome in lung cancer: expanding approaches to epigenetic therapy
M Jakopovic, A Thomas, S Balasubramaniam, D Schrump, G Giaccone, ...
Frontiers in oncology 3, 261, 2013
Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257
I Ofotokun, LH Na, RJ Landovitz, HJ Ribaudo, GA McComsey, C Godfrey, ...
Clinical Infectious Diseases 60 (12), 1842-1851, 2015
The system can't perform the operation now. Try again later.
Articles 1–20